SCHEMBL5136299

SCHEMBL5136299

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccccc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.45
TSHR P16473 3/20 0.41
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDE4B Q07343 2/20 0.36
NR1H3 Q13133 1/20 0.36
PCK1 P35558 1/20 0.35
CRHR1 P34998 1/20 0.35
CYP19A1 P11511 1/20 0.35
CNR2 P34972 1/20 0.35
GNRHR P30968 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL647986 0.93 C5AR1 (0.43) C5AR1TSHRTP53GAAKDM4E
SCHEMBL5136473 0.92 C5AR1 (0.44) C5AR1TSHRTP53GAAKDM4E
SCHEMBL5136940 0.92 C5AR1 (0.43) C5AR1TSHRTP53GAAKDM4E
SCHEMBL5135688 0.91 C5AR1 (0.45) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135185 0.91 C5AR1 (0.43) C5AR1TSHRTP53GAAKDM4E
SCHEMBL5137577 0.91 C5AR1 (0.43) C5AR1TSHRTP53GAAKDM4E
SCHEMBL651094 0.90 TSHR (0.50) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5136944 0.90 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135975 0.90 KDM4E (0.48) C5AR1TSHRTP53KDM4EALDH1A1
SCHEMBL5135131 0.90 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed